A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)
The MELODY Study is a Phase 3 randomized, double-blind, placebo-controlled, single-dose study to determine if MEDI8897 will prevent medically attende…
Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 years
Pertaprime is a study designed to learn more about a new vaccine, called Pertagen®, to protect young adults against pertussis “whooping cough”.
BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure (BRACE) Trial
This trial will determine whether BCG vaccination reduces the incidence and severity of COVID-19 but also whether BCG vaccination reduces other respi…
A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age
This study aims to investigate a new vaccine which has been developed to protect children from RSV.